Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. - Test2 - elhamkhani - TriplyDB

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.

http://www.wikidata.org/entity/Q38289423

about

Characterization of miR-122-independent propagation of HCV.Clinical development of hepatitis C virus host-targeting agents.Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV.Viruses and miRNAs: More Friends than Foes.Viral persistence, liver disease and host response in Hepatitis C-like virus rat model.The Clinical Application of MicroRNAs in Infectious Disease miRNA independent hepacivirus variants suggest a strong evolutionary pressure to maintain miR-122 dependence.Therapeutic prospects of microRNAs in cancer treatment through nanotechnology.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.Silencing a Multifunctional microRNA Is Beneficial for Stroke Recovery.Functional sequestration of microRNA-122 from Hepatitis C Virus by circular RNA sponges.MicroRNA-mediated dynamic control of mucosal immunity.Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy.Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors.A General Overview on Non-coding RNA-Based Diagnostic and Therapeutic Approaches for Liver Diseases On the Importance of Host MicroRNAs During Viral Infection Circular RNAs: Characteristics, Function and Clinical Significance in Hepatocellular Carcinoma

P2860

Q33719172-D7A1E9A5-8419-4BC1-BB75-5772D3219D7E Q37662513-7D732D3C-C41B-4E30-AF9F-AB75ED8DFF71 Q38734734-0ABBE9A1-2B94-4FB6-B9C6-01D5DFDFAAEB Q38735359-9E04ED3B-46BE-4DBF-BD1A-3B933FCDF661 Q39336975-63C83CB4-A735-4E39-BA2C-025916A4B407 Q40062848-D06BEDDB-2D09-4EC3-A5FA-99D4711DEB8C Q41921194-CBFBE928-2A9D-4057-934B-8C1C1800DD45 Q47148272-8012D3A2-FC74-437A-B765-FEE6DB50A881 Q48219725-94B32DB9-93BB-462C-99FF-C0D1D146DB19 Q48263612-0F32E18C-BA2B-4A79-832C-B40CA46AFF4B Q52661746-B9F9496F-E5B7-4BA7-BBC7-E6D895ABBE85 Q52682787-37748D72-E4A4-4077-A2C6-13246E06E373 Q52688461-142E0D68-D614-4C7A-8086-135AF6823494 Q52726764-4E27B698-CE68-413C-ABD9-4ECD46F7ADA6 Q55403266-1ED14C93-ACDE-4A1F-BBA5-978716F4AA25 Q57169221-E131FF76-B954-45D3-8540-4C038C6273DF Q58586274-F4A79F86-B7AB-458E-8574-8D9DA293E99C Q58802907-7ACF5198-CAC7-4B8B-91E7-949233209817

P2860

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.

http://www.wikidata.org/entity/Q38289423

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Safety, tolerability, and anti ...... , randomised controlled trial.

@en

type

label

Safety, tolerability, and anti ...... , randomised controlled trial.

@en

prefLabel

Safety, tolerability, and anti ...... , randomised controlled trial.

@en

P1433

Q38289423-56CC61CB-349C-4822-A599-BEA142561FC0

P1476

Q38289423-ADE8212F-B4CC-4020-8CB5-99E245C7CF03

P2093

Q38289423-0929802F-80BB-4C79-AA1A-DE649CEB9B71

Q38289423-10E97DDA-83DC-42E7-A738-F1CF7391EBB2

Q38289423-16C48772-155A-4DEE-9851-7258CCD57FC7

Q38289423-3517C451-A02C-4DA4-9626-AC1A67579984

Q38289423-38301D39-4FE0-40EC-8E50-54AAA753DEFF

Q38289423-48B06E00-B6BB-49B6-BD75-CBB1E46FD478

Q38289423-5A40BC6B-EC2B-456F-B0CA-58F4BCA27B12

Q38289423-5C221F6C-C750-46D3-9183-D4078AA8C14E

Q38289423-675E0B16-D743-42F2-A311-7BC8682DFDF8

Q38289423-7662558C-1048-4754-80BB-B0D504850164

P304

Q38289423-10865553-5D00-4DA9-B691-4CE75EF1FD1F

P31

Q38289423-843D90AC-4761-4303-8B70-007C40308E41

P356

Q38289423-1EA9756A-2E62-4423-A415-7B354839BC42

P407

Q38289423-AEC0FA36-847A-4356-B6F6-3CE9E63587FC

P433

Q38289423-3618FF78-76B6-4C6D-8A08-7DE8B90BABF3

P478

Q38289423-5F654C83-AAAF-44CE-825A-ACB85D4AAA21

P50

Q38289423-B9DA3FC7-0DCC-4360-8DD0-99CCC8D913DA

P577

Q38289423-764C9E2A-79EB-437A-8980-943D22F5BA57

P698

Q38289423-F92AE3D0-9025-4A49-97AB-FE8B6AA4B353

P356

S0140-6736(16)31715-9

P1433

P1476

Safety, tolerability, and anti ...... , randomised controlled trial.

@en

P2093

Ad C van Nuenen

http://www.w3.org/2001/XMLSchema#string

Adam Pavlicek

http://www.w3.org/2001/XMLSchema#string

Amy K Patick

http://www.w3.org/2001/XMLSchema#string

Eva van der Veer

http://www.w3.org/2001/XMLSchema#string

Femke Stelma

http://www.w3.org/2001/XMLSchema#string

Hendrik W Reesink

http://www.w3.org/2001/XMLSchema#string

J Marleen de Vree

http://www.w3.org/2001/XMLSchema#string

Jacqueline Blem

http://www.w3.org/2001/XMLSchema#string

Janke Schinkel

http://www.w3.org/2001/XMLSchema#string

John Grundy

http://www.w3.org/2001/XMLSchema#string

P304

709-717

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(16)31715-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

10070

http://www.w3.org/2001/XMLSchema#string

P478

389

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28087069

http://www.w3.org/2001/XMLSchema#string